关于公司 2024 年度利润分配预案的公告 证券代码：301092 证券简称：争光股份 公告编号：2025-010 浙江争光实业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、分配比例/转增比例：每 10 股派现金红利 2.60 元（含税）。 2、本次利润分配以现有总股本 134,053,484 股扣除公司目前回 购专户的股份数 428,000 股后的总股本 133,625,484 股为基数。 3、若自利润分配预案披露日至实施权益分派方案的股权登记日 期间公司股本发生变动，将按分派比例不变的原则相应调整现金红利 派发总额。 一、审议程序 浙江争光实业股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第六届董事会第十二次会议和第六届监事会第十一次会 议，审议通过了《关于公司 2024 年度利润分配预案的议案》。本次 利润分配预案尚需经公司股东大会审议通过后方可实施。 1.董事会审议情况 公司于 2025 年 4 月 24 日召开第六届董事会第十二次会议，会议 以 7 票同意，0 票反对，0 票弃权的表决结果， ...

Financial Performance - The company's revenue for Q1 2025 was CNY 133,050,946.32, representing a 12.66% increase compared to CNY 118,104,468.14 in the same period last year[5] - Net profit attributable to shareholders decreased by 7.41% to CNY 24,237,160.12 from CNY 26,177,483.07 year-on-year[5] - The net profit after deducting non-recurring gains and losses increased by 16.34% to CNY 22,416,986.00 compared to CNY 19,269,295.65 in the previous year[5] - Total operating revenue for the current period reached ¥133,050,946.32, an increase of 12.5% compared to ¥118,104,468.14 in the previous period[23] - Net profit for the current period was ¥24,237,160.12, a decrease of 7.4% from ¥26,177,483.07 in the previous period[24] - Basic and diluted earnings per share were both ¥0.18, down from ¥0.20 in the previous period[25] Cash Flow and Assets - The net cash flow from operating activities was CNY 15,062,628.83, down 12.92% from CNY 17,296,739.60 in the same period last year[5] - Cash flow from operating activities generated a net amount of ¥15,062,628.83, compared to ¥17,296,739.60 in the previous period, indicating a decline of 12.9%[25] - Total assets at the end of the reporting period were CNY 2,180,743,706.43, a decrease of 1.34% from CNY 2,210,322,450.41 at the end of the previous year[5] - Current assets decreased from CNY 1,310,787,579.12 to CNY 1,233,065,142.01, reflecting a decline of approximately 5.9%[19] - Cash and cash equivalents decreased from CNY 577,544,815.73 to CNY 551,634,014.84, a reduction of about 4.5%[19] - The ending balance of cash and cash equivalents was $193,191,976.60, down from $264,182,462.31 in the previous period[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,854[12] - The largest shareholder, Shen Jianhua, holds 51.83% of the shares, totaling 69,480,000 shares[13] - Shareholders' equity attributable to the parent company increased by 1.34% to CNY 1,911,387,875.57 from CNY 1,886,045,107.20 at the end of the previous year[5] - Total equity increased to ¥1,911,387,875.57 from ¥1,886,045,107.20, reflecting a growth of 1.3%[22] Liabilities and Expenses - Total liabilities decreased to ¥269,355,830.86 from ¥324,277,343.21, a reduction of 16.9%[22] - Total operating costs amounted to ¥108,226,348.03, up from ¥95,592,210.82, reflecting a growth of 13.7%[23] - Research and development expenses were ¥7,111,293.08, slightly down from ¥7,233,115.31 in the previous period[23] - The company reported a decrease in interest income to ¥3,280,193.78 from ¥4,220,271.04, a decline of 22.3%[24] Other Income and Comprehensive Income - The company reported a significant increase of 2469.82% in other income, amounting to CNY 19,333.77, primarily due to increased compensation and fines received[11] - Other comprehensive income after tax was reported at -¥179,507.24, compared to a positive amount of ¥254,226.42 in the previous period[22] Investments and Financing Activities - Cash inflow from investment activities totaled $435,560,236.58, an increase from $417,215,552.45 in the previous period[26] - Cash outflow for investment activities was $463,602,257.15, compared to $443,768,810.44 previously, resulting in a net cash flow of -$28,042,020.57[26] - Cash outflow from financing activities amounted to $1,181,056.68, a decrease from $6,988,124.11 in the prior period, leading to a net cash flow of -$1,181,056.68[26] Audit and Accounting Standards - The company did not undergo an audit for the first quarter report[27] - The new accounting standards will be first implemented starting in 2025[28]

Financial Performance - The company's operating revenue for 2024 was CNY 571,839,030.51, representing an increase of 8.67% compared to CNY 526,200,402.55 in 2023[22] - The net profit attributable to shareholders for 2024 was CNY 102,995,483.38, a decrease of 5.33% from CNY 108,791,131.72 in 2023[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 87,705,450.24, down 5.72% from CNY 93,022,187.27 in 2023[22] - The net cash flow from operating activities for 2024 was CNY 82,657,049.60, a decline of 4.27% compared to CNY 86,344,182.88 in 2023[22] - The total assets at the end of 2024 amounted to CNY 2,210,322,450.41, an increase of 8.38% from CNY 2,039,438,290.26 at the end of 2023[22] - The net assets attributable to shareholders at the end of 2024 were CNY 1,886,045,107.20, reflecting a growth of 3.66% from CNY 1,819,379,854.45 at the end of 2023[22] - The basic earnings per share for 2024 were CNY 0.77, down 4.94% from CNY 0.81 in 2023[22] - The weighted average return on net assets for 2024 was 5.58%, a decrease from 6.17% in 2023[22] Market and Industry Position - The company operates in the ion exchange and adsorption resin industry, which is classified as a strategic emerging industry, with applications expanding into high-end industrial water, food and drinking water, nuclear industry, electronics, biomedicine, and environmental protection[31] - The market for ion exchange and adsorption resins is expected to grow due to increasing demand from various sectors, including clean energy and biomedicine, driven by national policies and consumer health needs[32] - The company has established a strong presence in international markets, exporting products to countries such as Germany, Switzerland, Russia, Italy, South Korea, the USA, and Africa, serving major clients like BRITA and Mitsubishi Chemical[36] Research and Development - As of December 31, 2024, the company has 84 R&D personnel, representing 21.31% of total employees, indicating a strong focus on innovation and technical development[37] - The company has been recognized as a "National High-tech Enterprise" and a "National Manufacturing Single Champion Demonstration Enterprise," highlighting its commitment to innovation and quality[37] - The company aims to enhance traditional products while breaking the technological monopoly of developed countries and promoting domestic alternatives[37] - The company has achieved significant advancements in production technology, being one of the few in the industry to master high-end ion exchange and adsorption resin production techniques[37] - In 2024, the company introduced 2 senior technical professionals and applied for 12 invention patents[38] - The company has established a research and development model focused on independent and collaborative efforts, with a strong emphasis on new product and application development[46] Production and Operations - The procurement strategy is based on "sales-driven production" and "production-driven purchasing," ensuring a balance between safety stock and market demand[47] - The production process is characterized by "small batch, multiple varieties, and flexibility," utilizing advanced distributed control systems for quality consistency[48] - The sales model primarily relies on direct sales, supplemented by agents and trade partners, with a dedicated sales department for market expansion[49] - The company has a designed capacity of 22,050 tons for ion exchange and adsorption resins, with a capacity utilization rate of 113.48%[61] - The company has completed the construction of a 15,000-ton food-grade resin production line and is progressing with a 39,000-ton ion exchange and adsorption resin project, which is 60% complete[61] Financial Management and Investment - The company raised a total of RMB 121,033.34 million through its public offering, with a net amount of RMB 109,997.56 million after deducting underwriting and related fees[108] - As of December 31, 2024, the company has utilized RMB 89,272.32 million of the raised funds, representing an 81.16% usage rate[108] - The company has a remaining balance of RMB 20,725.24 million in unutilized funds, which is currently held in a dedicated account[108] - The company has incurred RMB 27.51 million in other expenses related to the fundraising process[108] - The company has approved the use of up to RMB 6 billion of idle funds for cash management, ensuring that it does not affect normal operations[111] Environmental Compliance - The environmental protection administrative license was re-applied on November 13, 2024, valid until November 12, 2029[196] - The company adheres to the synthetic resin industrial pollutant discharge standards (GB31572-2015) and petroleum chemical industry pollutant discharge standards (GB31571-2015)[195] - The total COD discharge for Ningbo Zhangguang Resin Co., Ltd. was 23.24 mg/L, which is below the standard of 24.45 mg/L[197] - The total ammonia nitrogen discharge for Ningbo Zhangguang Resin Co., Ltd. was 3.10 mg/L, below the standard of 3.26 mg/L[197] - The company has established a rainwater and sewage diversion system, ensuring wastewater treatment meets standards before discharge[199] Corporate Governance - The company has a complete governance structure, including a shareholders' meeting, board of directors, and supervisory board, ensuring independent management[144] - The company operates independently from its controlling shareholders in terms of assets, personnel, finance, institutions, and business[139] - The company has established an independent personnel management system, ensuring that senior management does not hold positions in related parties outside of subsidiaries[141] - The company has a governance structure with a clear distinction between executive and independent directors, ensuring checks and balances[151] Employee Management - The company has a total of 394 employees at the end of the reporting period, with 69 in the parent company and 325 in major subsidiaries[168] - The professional composition includes 204 production personnel, 43 sales personnel, 84 technical personnel, 8 financial personnel, and 55 administrative personnel[168] - The company has implemented a comprehensive training plan for 2024, including safety education for new employees and various skill training sessions[171] - The company has established a comprehensive employee benefits package, including five social insurances and one housing fund[169] Dividend and Profit Distribution - The company plans to distribute a cash dividend of 2.60 CNY per 10 shares (including tax), totaling 34,649,025.84 CNY for the 2023 fiscal year[173] - The total distributable profit for the year is 337,460,622.75 CNY, with the cash dividend accounting for 100% of the total profit distribution[176] - The decision-making process for the profit distribution plan is complete and complies with the company's articles of association and shareholder resolutions[173]

| 301479 | 弘景光电 | 117.50 | 27.56 | 8.29 | | --- | --- | --- | --- | --- | | 002583 | 海能达 | 13.11 | 27.56 | 1.31 | | 300773 | 拉卡拉 | 25.55 | 27.21 | 20.01 | | 001356 | 富岭股份 | 15.07 | 27.09 | -5.81 | | 001382 | 新亚电缆 | 23.17 | 26.93 | 0.52 | | 835892 | 中科美菱 | 21.05 | 26.78 | 4.47 | | 600644 | 乐山电力 | 12.94 | 26.54 | 10.03 | | 920106 | 林泰新材 | 136.00 | 26.47 | 10.92 | | 603110 | 东方材料 | 19.10 | 26.46 | 1.60 | | 301629 | 矽电股份 | 175.18 | 26.20 | 1.85 | | 300605 | 恒锋信息 | 16.11 | 26.19 | -6.99 | | 300892 | 品渥食品 | 40.70 ...

Investment Rating - The report maintains an "Overweight" rating for the basic chemical industry [1] Core Viewpoints - DuPont is under investigation for antitrust violations in China, which may accelerate the domestic substitution process for ion exchange resins [5] - DuPont's sales in the Asia-Pacific region account for 43% of its total sales, with significant contributions from electronic and water treatment sectors [4] - The water treatment and protection business of DuPont generated sales of $5.6 billion in 2023, with a slight decline expected in 2024 [5] - The investigation could benefit domestic leaders in ion exchange resins, such as Bluestar Technology and Zhengguang Co., as they may capture market share previously held by DuPont [5][6] Summary by Sections Industry Overview - The global market for ion exchange resins used in ultra-pure water production reached $1.34 billion in 2023 and is projected to grow to $2.3 billion by 2030, with a CAGR of 8.5% from 2024 to 2030 [6] Company Insights - DuPont plans to spin off its electronic business by November 2025, while retaining its water treatment business [4] - The water treatment business's sales are expected to decline slightly in 2024 but show growth in the second half of the year [5] Market Dynamics - The antitrust investigation may catalyze the domestic production of ion exchange resins, particularly in industrial water treatment [5] - Domestic manufacturers are actively pursuing high-end applications in sectors like semiconductors and nuclear industries [6]

Investment Rating - The report maintains a "Buy" rating for the ion exchange resin industry, indicating a strong potential for investment returns exceeding 15% over the next 6-12 months [5]. Core Insights - The demand for ion exchange resins is rapidly growing, particularly in emerging fields such as nuclear industry, biomedicine, and electronic applications, which presents significant development opportunities for the industry [3]. - The high-end market for ion exchange resins is dominated by international leaders, while domestic companies are making strides in localizing production and enhancing competitiveness [2]. - The report emphasizes the importance of new separation and purification processes in various industries, highlighting the critical role of ion exchange resins in ensuring operational efficiency and product quality [3]. Summary by Sections Industry Overview - Ion exchange resins are versatile organic polymers used for separation and purification processes across various sectors, including pharmaceuticals, food processing, and environmental protection [1]. - The industry is witnessing increased R&D investments and market expansion, leading to the development of specialized resins with unique functionalities [1]. Market Competition - The ion exchange resin market is structured into three tiers: leading multinational corporations (e.g., Dow Chemical, Lanxess) dominate the high-end market, while domestic players (e.g., Bluestar Technology, ZG Co.) are advancing in local market share and international brand recognition [2]. - Smaller enterprises in the industry face challenges due to limited resources and technology, primarily serving as suppliers or niche players [2]. Future Prospects - The report forecasts robust growth in the ion exchange resin market driven by increasing demand in nuclear power, metallurgy, and other high-tech industries, with significant potential for domestic companies to replace imports [3]. - Key companies to watch include Bluestar Technology and ZG Co., which are positioned to benefit from the ongoing trend of domestic substitution and product upgrades [3].

证券代码：301092 证券简称：争光股份 公告编号：2025-002 浙江争光实业股份有限公司 关于回购股份进展暨回购实施结果的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江争光实业股份有限公司（以下简称"公司"）于 2024 年 2 月 6 日召开第六届董事会第六次会议，审议通过了《关于回购公司股 份方案的议案》，同意公司拟使用自有资金以集中竞价交易方式回购 公司已发行的人民币普通股（A 股）股票，用于实施股权激励或员工 持股计划。本次回购的资金总额不低于 1,000 万元且不超过 2,000 万 元（均含本数），回购价格不超过 36.00 元/股（含本数），按照回 购价格上限 36.00 元/股(含）和回购资金总额下限、上限测算，预计 回购股份数量为 27.78 万股至 55.56 万股，占公司总股本的比例为 0.21%至 0.42%，具体回购股份的数量以回购期满时或者回购股份实 施完毕时实际回购的股份数量为准。本次回购股份的实施期限自公司 董事会审议通过本次回购股份方案之日起不超过十二个月。具体内容 详见公司分别于 2024 年 2 月 6 ...

证券代码：301092 证券简称：争光股份 公告编号：2025-001 浙江争光实业股份有限公司 关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江争光实业股份有限公司（以下简称"公司"）于 2024 年 2 月 6 日召开第六届董事会第六次会议，审议通过了《关于回购公司股 份方案的议案》，同意公司拟使用自有资金以集中竞价交易方式回购 公司已发行的人民币普通股（A 股）股票，用于实施股权激励或员工 持股计划。本次回购的资金总额不低于 1,000 万元且不超过 2,000 万 元（均含本数），回购价格不超过 36.00 元/股（含本数），按照回 购价格上限 36.00 元/股(含）和回购资金总额下限、上限测算，预计 回购股份数量为 27.78 万股至 55.56 万股，占公司总股本的比例为 0.21%至 0.42%，具体回购股份的数量以回购期满时或者回购股份实 施完毕时实际回购的股份数量为准。本次回购股份的实施期限自公司 董事会审议通过本次回购股份方案之日起不超过十二个月。具体内容 详见公司分别于 2024 年 2 月 6 日、20 ...

2024 现场检查手段：对上市公司管理层有关人员进行访谈；查看上市公司的主要管 理场所；对有关文件、原始凭证及其他资料或客观状况进行查阅、复制、记录。 | 1.是否建立了防止控股股东、实际控制人及其 他关联人直接或者间接占用上市公司资金或 | √ | | | --- | --- | --- | | 者其他资源的制度 | | | | 2.控股股东、实际控制人及其他关联人是否不 存在直接或者间接占用上市公司资金或者其 | √ | | | 他资源的情形 | | | | 3.关联交易的审议程序是否合规且履行了相应 | | √ | | 的信息披露义务 | | | | 4.关联交易价格是否公允 | | √ | | 5.是否不存在关联交易非关联化的情形 | √ | | | 6.对外担保审议程序是否合规且履行了相应的 | | √ | | 信息披露义务 | | | | 7.被担保方是否不存在财务状况恶化、到期不 | | √ | | 清偿被担保债务等情形 | | | | 8.被担保债务到期后如继续提供担保，是否重 | | √ | | 新履行了相应的审批程序和披露义务 | | | | （五）募集资金使用 | | | | 现场检查手 ...

一、募集资金的情况概述 （一）募集资金的基本情况 根据中国证券监督管理委员会于 2021 年 8 月 27 日出具的《关于 同意浙江争光实业股份有限公司首次公开发行股票注册的批复》（证 监许可〔2021〕2803 号），浙江争光实业股份有限公司（以下简称 "公司"）首次公开发行人民币普通股（A）股 3,333.3334 万股，每 股发行价格为 36.31 元，募集资金总额为人民币 121,033.34 万元； 扣除发行费用后实际募集资金净额为人民币 109,997.56 万元。上述 募集资金已于 2021 年 10 月 25 日全部到账，并经天健会计师事务所 （特殊普通合伙）对公司首次公开发行股票的资金到位情况进行了审 验，并于 2021 年 10 月 25 日出具了《验资报告》（天健验〔2021〕 580 号）。公司及子公司已对募集资金进行专户管理，并与开户银行、 保荐人签署了募集资金监管协议，上述募集资金已经全部存放于募集 资金专户管理。 （二）募集资金投资项目情况 根据公司《首次公开发行股票并在创业板上市招股说明书》，公 司首次公开发行人民币普通股（A 股）股票的募集资金在扣除发行费 用后将拟投资于以下 ...